Anbio Biotechnology is breaking new ground in the European market with the launch of its premier product, the AF-100 C, a state-of-the-art compact fluorescent immunoassay analyser set to redefine the standards of point-of-care diagnostics. Armed with over 70 assays, the AF-100 C is designed to fortify the capabilities of healthcare providers throughout the EU, thus elevating patient diagnostics and care.
Anbio Biotechnology (Anbio), a luminary in the global in vitro diagnostics industry, is excited to announce the debut of its wide-ranging “Point of Care” product assortment within the European Union. This introduction marks a significant chapter for Anbio, heralding new partnerships with EU distributors and healthcare providers and highlighting the company’s commitment to bringing advanced diagnostic technologies to the EU market.
Anbio is esteemed for its trailblazing approach and commitment to quality, moving beyond its roots as a Covid test kit supplier to become a multifaceted developer and manufacturer of a broad spectrum of diagnostic instruments. “Our mission is to revolutionize diagnostics by offering tailored and accessible solutions, including laboratory, wellness, at-home, and point-of-care diagnostics. We are committed to affordability and continuous innovation in life sciences that serve to advance human heath,” Michael Lau, CEO of Anbio, conveyed.
Advanced Analyzer Equips Healthcare Providers with Over 70 Key Tests
The forefront of Anbio’s European campaign is the AF-100 C analyzer, a sophisticated, single-channel, portable, rechargeable compact fluorescent Immunoassay (FIA) analyzer. This robust device, complemented by over 70 CE-marked assays for various analytes such as inflammation indicators, diabetes, cancer markers, hormones, enzymes, and infectious diseases, is expected to dramatically transform the EU’s clinical diagnostics field.
“The Anbio AF-100 C is a game-changer for clinical diagnostics, supplying healthcare providers with a cost-effective, comprehensive, and reliable solution for rapid point-of-care testing,” Lau noted. Despite its compact footprint, the AF-100 C offers high throughput and is adaptable to diverse clinical scenarios, from small medical practices to intensive emergency units. Its intuitive operation and resilient battery, supporting up to 8 hours of continuous testing, ensure healthcare professionals can deliver exceptional patient care with efficiency and precision.
Rapid and Accurate Diagnostics Set to Enhance Healthcare Outcomes
Anbio’s comprehensive FIA lineup, delivering swift results in 3 to 15 minutes, signals a significant advancement in diagnostic technologies. With reagents leveraging RFID chip technology for utmost accuracy and a 24-month shelf life at room temperature, Anbio is prepared to address the immediate challenges faced by Europe’s healthcare system.
As Anbio Biotechnology makes its entry into the EU market, it extends an invitation to distributors and healthcare practitioners to discover its cutting-edge diagnostic innovations. Committed to improving patient care through affordable, precise, and dependable diagnostics, Anbio is keen to collaborate with healthcare professionals throughout the EU.
